The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Background: Afatinib is a second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has been approved by the Food and Drug Administration for the treatment of advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. We performed a meta-analysis to asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chi, Li, Yun, Ke, Li, Cao, Lejie, Fan, Pingsheng, Wu, Zhiwei, Wu, Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400820/
https://www.ncbi.nlm.nih.gov/pubmed/30854094
http://dx.doi.org/10.7150/jca.27528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400820/
https://www.ncbi.nlm.nih.gov/pubmed/30854094
http://dx.doi.org/10.7150/jca.27528

Ejemplares similares